Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives $8.75 Average PT from Brokerages

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) has earned a consensus rating of “Moderate Buy” from the nine brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $8.75.

A number of research firms have recently issued reports on AUTL. Truist Financial upgraded Autolus Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Mizuho reduced their price objective on Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 31st. Needham & Company LLC reissued a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research note on Thursday, April 9th. Weiss Ratings upgraded Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 6th. Finally, Wall Street Zen raised Autolus Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 13th.

Autolus Therapeutics Trading Down 8.1%

Shares of NASDAQ AUTL opened at $1.48 on Tuesday. Autolus Therapeutics has a 12-month low of $1.18 and a 12-month high of $2.70. The stock has a market cap of $393.92 million, a PE ratio of -1.36 and a beta of 2.04. The company has a 50-day moving average of $1.62 and a 200 day moving average of $1.56.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.02. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%. The company had revenue of $26.22 million during the quarter, compared to the consensus estimate of $26.27 million. On average, sell-side analysts forecast that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Hedge funds have recently modified their holdings of the company. Invesco Ltd. increased its position in Autolus Therapeutics by 53.3% during the first quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock worth $51,000 after purchasing an additional 11,381 shares during the last quarter. Jane Street Group LLC boosted its holdings in Autolus Therapeutics by 809.4% in the 1st quarter. Jane Street Group LLC now owns 102,493 shares of the company’s stock valued at $159,000 after purchasing an additional 91,222 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Autolus Therapeutics by 90.5% in the 2nd quarter. Geode Capital Management LLC now owns 164,314 shares of the company’s stock valued at $375,000 after buying an additional 78,058 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Autolus Therapeutics by 41.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock valued at $88,000 after buying an additional 11,289 shares during the period. Finally, Bank of America Corp DE increased its holdings in shares of Autolus Therapeutics by 2,891.7% during the 2nd quarter. Bank of America Corp DE now owns 975,135 shares of the company’s stock worth $2,223,000 after buying an additional 942,540 shares during the last quarter. Hedge funds and other institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.